The PCDx test provides patients and physicians with a blueprint of the underlying mechanisms of a patient’s disease, potential treatment approaches, and comprehensive inventory of relevant clinical trials. It identifies actionable classes of genomic alterations in hundreds of cancer-related genes, including:
THE PCDx ADVANTAGE
PCDx is Fast
Paradigm promises a clinically relevant turnaround time. Customers can expect 5 business days from sample receipt to reporting ensures continuity of clinical care.
PCDx is Accurate
Comprehensive NGS results on as little as 1-2 slides (+ 1 slide for H&E + 1 slide per IHC)
PCDx is Effective
Looks at biomarkers associated with >90 FDA approved therapies and 24 combinations.
Paradigm brings cutting-edge diagnostics and biomarker driven clinical trials to benefit cancer patients.
Through Next-Gen Sequencing (NGS), and other biomarker analysis, the Paradigm Cancer Diagnostic (PCDx) test is able to provide the treating clinician with information about the genomic and proteomic landscape of a patient’s cancer, helping personalize each patient’s course of treatment.